In recent years, due to air pollution, smoking and other issues, the incidence of lung cancer in China is gradually increasing, and the fastest growth rate, currently accounting for nearly a quarter of the overall incidence of cancer in China, China's annual increase in the number of new lung cancer patients The world total is about 30%. Statistics show that the mortality rate of lung cancer in China has reached 37% per 100,000, an increase of 465% compared with 30 years ago. The situation is not optimistic.
On April 25th, Boston Scientific announced its respiratory intervention products: Ultraflex tracheobronchial stent and CRE Pulmonary balloon dilatation catheter were officially launched in China. These two stents and balloons designed specifically for the respiratory tract fill the gaps in China's airway stent graft and tertiary expansion technology.
Ultraflex tracheobronchial stents are made of nickel-titanium alloy wire made by a unique weaving method. They can adapt to a variety of complex airway shapes, have stable support, and have excellent flexibility, which can greatly improve patient comfort. The stent system is available in a range of sizes and sizes to provide a wide range of diameters and diameters to meet different treatment needs. The CRE Pulmonary balloon dilatation catheter continuously and progressively expands the stenosis with its three-stage expansion technique, helping to eliminate the need to expand multiple airways for multiple balloons. These two respiratory intervention techniques are mainly used to expand the narrow airway tree to treat tracheobronchial stenosis caused by malignant tumors, which will help improve the treatment effect of airway stenosis caused by domestic lung cancer and other factors, and improve the quality of life of patients.
Professor Wang Guangfa, director of the Department of Respiratory Medicine, Peking University First Hospital, said: "Respiratory intervention has the advantages of minimally invasive and low side effects. For many patients with advanced lung cancer who have lost their chance of surgery, they can ensure normal breathing and prolong their survival time. Deputy Director Li Shiyue of Guangzhou Hoyan Research Institute believes that: Boston Scientific Respiratory Intervention Products have the characteristics of exact curative effect, small trauma, high safety and more comfortable use of patients. This Boston Scientific will introduce respiratory intervention products into China, which will be effective. Help improve and improve the survival rate and quality of life of lung cancer patients in China.
Since implementing the “Innovation Shockwave†strategy in the Chinese market, Boston Scientific has introduced more than 50 innovative medical products every year for three consecutive years. Wang Xin, vice president of Boston Science and general manager of North Asia, said: "The introduction of this respiratory intervention product portfolio marks the firm determination of Boston Scientific to deepen the Chinese market and promote the development of domestic respiratory intervention. We will always adhere to effective innovation. Promote technological advancement and provide more efficient and safe medical solutions for Chinese patients."
Disposable Gel,Moisturizing Hand Sanitizer,Hand Sanitizer,Hand Sanitizer Dispenser
Wuxi Keni Daily Cosmetics Co.,Ltd , https://www.wxkenidaily.com